EUVIMEDEUVIMED entdecken
VergleichsstudieÜbersichtsarbeitOpen Access

Comparison of Amino Acid Positron Emission Tomographic Radiotracers for Molecular Imaging of Primary and Metastatic Brain Tumors

Csaba Juhász, Shalini Dwivedi, David O Kamson, Sharon K Michelhaugh, Sandeep Mittal

Molecular Imaging · 01.08.2014 · 13 (6)

DOI: 10.2310/7290.2014.00015 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Molecular Imaging, online erschienen am 01.08.2014. Verfasst von Csaba Juhász und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Radiopharmaceuticals. Die Arbeit wurde bisher 126-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Positron emission tomography (PET) is an imaging technology that can detect and characterize tumors based on their molecular and biochemical properties, such as altered glucose, nucleoside, or amino acid metabolism. PET plays a significant role in the diagnosis, prognostication, and treatment of various cancers, including brain tumors. In this article, we compare uptake mechanisms and the clinical performance of the amino acid PET radiotracers (L-[methyl- 11 C]methionine [MET], 18 F-fluoroethyl-tyrosine [FET], 18 F-fluoro-L- dihydroxy-phenylalanine [FDOPA], and 11 C-alpha-methyl-L-tryptophan [AMT]) most commonly used for brain tumor imaging. First, we discuss and compare the mechanisms of tumoral transport and accumulation, the basis of differential performance of these radioligands in clinical studies. Then we summarize studies that provided direct comparisons among these amino acid tracers and to clinically used 2-deoxy-2[ 18 F]fluoro-D-glucose [FDG] PET imaging. We also discuss how tracer kinetic analysis can enhance the clinical information obtained from amino acid PET images. We discuss both similarities and differences in potential clinical value for each radioligand. This comparative review can guide which radiotracer to favor in future clinical trials aimed at defining the role of these molecular imaging modalities in the clinical management of brain tumor patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsAmino AcidsBrain NeoplasmsCarbon RadioisotopesFluorine RadioisotopesGlucoseHumansNeoplasm MetastasisPositron-Emission TomographyVitamin U

Substanzen

Amino AcidsCarbon RadioisotopesFluorine RadioisotopesRadiopharmaceuticalsVitamin UGlucose

Förderung

  • NCI NIH HHS

Zitieren

APA

Juhász, C., Dwivedi, S., Kamson, D. O., Michelhaugh, S. K., & Mittal, S. (2014). Comparison of Amino Acid Positron Emission Tomographic Radiotracers for Molecular Imaging of Primary and Metastatic Brain Tumors. Molecular Imaging, 13(6). https://doi.org/10.2310/7290.2014.00015

Vancouver

Juhász C, Dwivedi S, Kamson DO, Michelhaugh SK, Mittal S. Comparison of Amino Acid Positron Emission Tomographic Radiotracers for Molecular Imaging of Primary and Metastatic Brain Tumors. Molecular Imaging. 2014;13(6). doi:10.2310/7290.2014.00015

BibTeX
@article{Juhsz2014,
  author = {Juhász, Csaba and Dwivedi, Shalini and Kamson, David O and Michelhaugh, Sharon K and Mittal, Sandeep},
  title = {Comparison of Amino Acid Positron Emission Tomographic Radiotracers for Molecular Imaging of Primary and Metastatic Brain Tumors},
  journal = {Molecular Imaging},
  year = {2014},
  volume = {13},
  number = {6},
  doi = {10.2310/7290.2014.00015}
}
Kostenlos starten →